Asosiy kontentga oʻtish
Maqola

Structure‐Governed MXene Quantum Dots for Cancer Theranostics: From Quantum Confinement to Tumor‐Selective Catalytic and Photothermal Activation

Ghaleb OriquatFaculty of Allied Medical Sciences Hourani Center for Applied Scientific Research Al‐Ahliyya Amman University Amman JordanAziz KubaevDepartment of Maxillofacial Surgery Samarkand State Medical University Samarkand UzbekistanSanjar UsmanaliyevDepartment of Dermatovenerology and Cosmetology No. 1 Tashkent State Medical University Tashkent UzbekistanThaer Abdul AllhDepartment of Tqnyat Altkhdyr College Altqnyat Altbyh The Islamic University Najaf IraqFaris Anad MuhammadCollege of Pharmacy Alnoor University Nineveh IraqRajashree PanigrahiInstitute of Medical Sciences and Sum HospitalNeeraj BainsalUniversity Institute of Pharma Sciences Chandigarh University Mohali Punjab IndiaHadi NoorizadehYoung Researchers and Elite Club Tehran Branch Islamic Azad University Tehran Iran
Advanced Therapeuticsjournal2026en

Ochiq kirish: yoʻq

ABI

Annotatsiya

ABSTRACT MXene quantum dots (MQDs) have recently emerged as a compelling class of nanomaterials for cancer theranostics, owing to their confined electronic structure, multifunctional activation mechanisms, and favorable in vivo performance. In this review, the structure‐governed behavior of MQDs is systematically examined and interpreted, highlighting how their quantum‐scale architecture influences therapeutic functionality. The chemical and physical origins of functional diversity in MQDs are discussed, with an emphasis on dimensional miniaturization, electronic confinement, and structure–property relationships beyond biological contexts. Building on this foundation, recent advances in tumor‐selective catalytic and photothermal activation of MQDs are analyzed, highlighting Fenton‐like redox processes, near‐infrared photothermal conversion, and synergistic therapeutic modalities supported by in vivo evidence. Particular attention is given to tumor microenvironment modulation, spatiotemporal control, and imaging‐guided activation strategies that distinguish MQDs from conventional nanotherapeutics. Finally, key challenges related to clinical advancement, manufacturing scalability, safety evaluation, and regulatory considerations are evaluated. By integrating fundamental structure‐driven insights with therapeutic and clinical perspectives, MQDs are positioned as a versatile and promising platform for next‐generation precision cancer theranostics.

Hali tarjima qilinmagan

Mavzular

Identifikatorlar

Iqtiboslar va manbalar